UKAR will be a collaborative epidemiological study delivered by BSAC in partnership with Aberdeen University and supported by industry partners. The Registry will initially be open for intravenous antibiotics, with a particular focus on multi-drug resistant organisms.
The registry will be overseen by an expert steering group to ensure appropriate consent and governance at all levels of implementation and will begin data collection by October 2021.
Companies wishing to join the registry and include their antimicrobial agents are invited to contact Tracey Guise, CEO by email.